Alector (ALEC) Non-Current Deffered Revenue (2018 - 2026)
Alector's (ALEC) quarterly Non-Current Deffered Revenue came in at $162.9 million in Q1 2026, down 4.37% year-on-year from $170.3 million in Q1 2025, and down 1.02% on a QoQ basis from $164.5 million in Q4 2025.
Alector (ALEC) Non-Current Deffered Revenue (2018 - 2026) Analysis & Trends
Alector (ALEC) has 9 years of Non-Current Deffered Revenue data on file, last reported at $162.9 million in Q1 2026.
- On a quarterly basis, Non-Current Deffered Revenue fell 4.37% year-over-year to $162.9 million in Q1 2026; TTM through Mar 2026 was $162.9 million, a 4.37% decrease from a year earlier, with the FY2025 full-year figure at $164.5 million, down 4.43% from the prior year.
- Non-Current Deffered Revenue for Q1 2026 stood at $162.9 million, down from $164.5 million in the prior quarter.
- Over the last five years, Non-Current Deffered Revenue for ALEC reached as high as $505.1 million in Q1 2022 and fell as low as $162.9 million in Q1 2026.
- Historically, Non-Current Deffered Revenue has averaged $262.9 million across 5 years, with a median of $204.6 million in 2024.
- Across the five-year window, Non-Current Deffered Revenue surged 378.83% in 2022 and plunged 52.54% in 2024, its largest moves.
- Year by year, Non-Current Deffered Revenue stood at $443.4 million in 2022, then slumped by 52.44% to $210.8 million in 2023, then slipped by 18.34% to $172.2 million in 2024, then slipped by 4.43% to $164.5 million in 2025, then fell by 1.02% to $162.9 million in 2026.
- Per Business Quant data, the three most recent Non-Current Deffered Revenue figures were $162.9 million in Q1 2026, $164.5 million in Q4 2025, and $167.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Alector | 164.78 Mn | -41.74 Mn | - | 162.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 162.87 Mn |
| Dec 31, 2025 | 164.54 Mn |
| Sep 30, 2025 | 167.27 Mn |
| Jun 30, 2025 | 168.87 Mn |
| Mar 31, 2025 | 170.31 Mn |
| Dec 31, 2024 | 172.17 Mn |
| Sep 30, 2024 | 192.78 Mn |
| Jun 30, 2024 | 199.58 Mn |
| Mar 31, 2024 | 204.58 Mn |
| Dec 31, 2023 | 210.85 Mn |
| Sep 30, 2023 | 229.85 Mn |
| Jun 30, 2023 | 245.34 Mn |
| Mar 31, 2023 | 431.08 Mn |
| Dec 31, 2022 | 443.37 Mn |
| Sep 30, 2022 | 386.36 Mn |
| Jun 30, 2022 | 413.90 Mn |
| Mar 31, 2022 | 505.13 Mn |
| Dec 31, 2021 | 334.42 Mn |
| Sep 30, 2021 | 344.53 Mn |
| Jun 30, 2021 | 96.21 Mn |